Biotechnology - Pharmaceutical, Novartis

Filter

Current filters:

PharmaceuticalNovartis

Popular Filters

1 to 25 of 48 results

Novartis links with Regenerex in cell therapy research collaboration

06-09-2013

Swiss drug major Novartis (NOVN: VX) has entered into an exclusive global licensing and research collaboration…

BiotechnologyCTL019HSC835ImmunologicalsLicensingNovartisPharmaceuticalRegenerexResearch

New therapies to spur acute myeloid leukemia market growth

27-08-2013

Driven by a boost in new therapies entering the market, as well as an increasing number of acute myeloid…

BiotechnologyCyclacel PharmaceuticalsMarkets & MarketingmidostaurinNovartisOncologyPharmaceuticalsapacitabineSunesis Pharmaceuticalsvosaroxin

Novartis enters into a collaboration for Il-17 inhibitor

06-08-2013

US biotech firm Ensemble Therapeutics, a company developing Ensemblins, a novel class of small molecule…

BiotechnologyEnsemble TherapeuticsImmunologicalsInflammatory diseasesLicensingNovartisPharmaceutical

Cheaper anti-cancer drug as effective as expensive disease-specific agent in treating wet AMD

21-07-2013

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness…

AvastinBiotechnologyEuropeFinancialLucentisNovartisOphthalmicsPharmaceuticalResearchRoche

Highlights from ASCO: Bayer's Nexavar; Novartis' Afinitor; and Amgen's talimogene laherparepvec

02-06-2013

The prestigious annual meeting of the American Society of Clinical Oncology (ASCO) kicked off this weekend…

AfinitorAmgenBayerBiotechnologyNexavarNovartisOncologyOnyx PharmaceuticalsPharmaceuticalResearchtalimogene laherparepvec

NICE rejects Avastin for ovarian cancer, but backs Lucentis for RVO

22-05-2013

The UK's drugs watchdog the National Institute for Health and Care Excellence (NICE) has this morning…

AvastinBiotechnologyEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPricingRegulationRoche

UK's NICE gives final guidance on Esbriet, Orencia and Xolair

24-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Positive NICE recommendation for Novartis' Lucentis, but not for Cell Thera's Pixuvri

11-04-2013

There was good news for Swiss drug major Novartis (NOVN: VX) this morning, when UK drugs watchdog the…

BiotechnologyCell TherapeuticsEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPixuvriPricingRegulation

Global epigenetic therapies market to increase at a CAGR of 10% through 2017

04-03-2013

The global epigenetic therapies market is expected to reach a total value of around $2.518 billion by…

belinostatBiotechnologyCelgeneFaridakGlobalMarkets & MarketingNovartisOncologypanobinostatPharmaceuticalSpectrum PharmaceuticalsTopotargetVidaza

Global orphan drugs market led by Roche's rituximab

26-02-2013

The global orphan drugs market is estimated to have increased at a compound annual growth rate (CAGR)…

BiotechnologyLucentisMarkets & MarketingNovartisPharmaceuticalRare diseasesRituxanRoche

Genentech Ph III study of omalizumab shows promise in CIU

25-02-2013

Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

Italy's antitrust body investigating Roche and Novartis for alleged cartel

21-02-2013

The Italian antitrust authority has opened a cartel investigation of Swiss drug majors Novartis (NOVN:…

AvastinBiotechnologyEuropeGenentechLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

Novartis/Incyte's Jakafi will be greatest growth driver in myelofibrosis market

31-01-2013

Through 2021, the continued uptake of Novartis (NOVN: VX)/Incyte's (Nasdaq: INCY) recently launched JAK-2…

BiotechnologyCYT387EuropeGilead SciencesIncyteJakafiMarkets & MarketingNorth AmericaNovartisOncologyPharmaceuticalYM Biosciences

FDA clears new use for Roche's Avastin and Novartis' Exjade

25-01-2013

The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

SOBI gains EMA approval for change of Kineret producer; Novartis drops NIC002 project

23-01-2013

Swedish Orphan Biovitrum (STO: SOBI) has received approval from the European Medicines Agency for the…

BiotechnologyBoehringer IngelheimCytos BiotechnologyKineretLicensingNIC002NovartisPharmaceuticalProductionRegulationSwedish Orphan Biovitrum

UK's NICE issues draft guideline for diagnosis and management of hepatitis B

17-01-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) is currently developing…

Anti-viralsBaracludeBiotechnologyBristol-Myers SquibbEuropeGilead SciencesNovartisPharmaceuticalPreveonPricingRegulationSebivoViread

Patient trust in drugmakers declining, new report shows

14-01-2013

Increasing numbers of pharmaceutical companies are seeking to redefine their relationships with patients,…

Abbott LaboratoriesBiotechnologyEli LillyGilead SciencesGlaxoSmithKlineGlobalJanssenLundbeckMarkets & MarketingNovartisNovo NordiskPfizerPharmaceuticalPricingResearchRoche

Small-molecule cancer drug revenues will reach $32.7 billion in 2016, says Visiongain

09-01-2013

The small-molecule targeted cancer therapy revenues will reach a value of $32.7 billion worldwide in…

BiotechnologyGleevecGlivecGlobalMarkets & MarketingNovartisOncologyPharmaceutical

Novartis' Gilenya MS patient share growth in Europe likely driven by improved product satisfaction and efficacy-related

09-12-2012

Swiss drug major Novartis' (NOVN: VX) Gilenya (fingolimod) has captured 5.4% of those multiple sclerosis…

AubagioBG-12Biogen IdecBiotechnologyEuropeGilenyaMarkets & MarketingNeurologicalNovartisPharmaceuticalSanofi

1 to 25 of 48 results

Back to top